系统评价荟萃分析重组人血管内皮抑制素联合吉西他滨和顺铂治疗非小细胞肺癌的疗效。
Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer.
机构信息
Yunyang County People's Hospital Oncology Department, Chongqing, China.
出版信息
J Healthc Eng. 2022 Mar 15;2022:3208780. doi: 10.1155/2022/3208780. eCollection 2022.
OBJECTIVE
To evaluate the efficacy of recombinant human endostatin combined with gemcitabine and cisplatin in the treatment of non-small-cell lung cancer (NSCLC).
METHODS
The databases of Cochrane Library, Embase, ClinicalTrials, PubMed, HowNet, Wanfang, and VIP were searched to collect randomized controlled trials (RCTs) of recombinant human endostatin combined with gemcitabine and cisplatin (experimental group) and gemcitabine combined with cisplatin (control group) for comparative study. The quality of literature was evaluated by bias risk assessment tools and related scales, and then meta-analysis was performed.
RESULTS
A total of 27 RCTs (1646 patients) were included. The results of meta-analysis showed that the effective rate ( < 0.000 01) and benefit rate ( < 0.000 01) of the experimental group were significantly higher than those of the control group, the incidence of leucopenia ( = 0.79), thrombocytopenia ( = 0.39), and gastrointestinal reaction ( = 0.85) were not statistically significant.
CONCLUSION
The combination of recombinant human endostatin, gemcitabine, and cisplatin can increase the efficacy and safety of NSCLC patients.
目的
评估重组人血管内皮抑制素联合吉西他滨和顺铂治疗非小细胞肺癌（NSCLC）的疗效。
方法
检索 Cochrane 图书馆、Embase、ClinicalTrials、PubMed、知网、万方和 VIP 数据库，收集重组人血管内皮抑制素联合吉西他滨和顺铂（实验组）与吉西他滨和顺铂（对照组）比较的随机对照试验（RCT）。采用偏倚风险评估工具和相关量表评价文献质量，然后进行荟萃分析。
结果
共纳入 27 项 RCT（1646 例患者）。荟萃分析结果显示，实验组的有效率（ < 0.000 01）和受益率（ < 0.000 01）显著高于对照组，白细胞减少症（ = 0.79）、血小板减少症（ = 0.39）和胃肠道反应（ = 0.85）的发生率无统计学意义。
结论
重组人血管内皮抑制素联合吉西他滨和顺铂可提高 NSCLC 患者的疗效和安全性。
Zotero 插件